Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143282 | 1.00 | HCAR2 (1.00) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9874572 | 0.98 | HCAR2 (0.96) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4212112 | 0.98 | HCAR2 (0.96) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31591277 | 0.93 | HCAR2 (0.86) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9117065 | 0.86 | HCAR2 (0.76) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5598744 | 0.85 | HCAR2 (0.74) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5598741 | 0.85 | HCAR2 (0.74) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9580713 | 0.85 | HCAR2 (0.73) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10332830 | 0.84 | HCAR2 (0.72) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10332828 | 0.84 | HCAR2 (0.72) | HCAR2ABCG2SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433928-A | Chemical silver plating liquid medicine and chemical silver plating method for 5G high-frequency circuit board | 深圳市板明科技股份有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-115058762-B | Tin settling agent for electrotinning process and use method thereof | 深圳市板明科技股份有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-115058762-A | Tin settling agent for electrotinning process and use method thereof | 深圳市板明科技股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-113912769-A | Temperature-resistant salt-tolerant gel foam system and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-01-11 | — | — | CN | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| EP-2969029-B1 | USE OF COSMETICALLY OR DERMATOLOGICALLY SAFE SUBSTITUTED MICHAEL ACCEPTORS FOR THE PREVENTION, REDUCTION OR PROPHYLAXIS OF THE TYROSINASE ACTIVITY OF THE HUMAN SKIN AND/OR THE LIGHTENING OF THE HUMAN SKIN | BEIERSDORF AG (DE) | 2018-07-11 | — | — | EP | claimed |
| US-9999678-B2 | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof | CONTIPRO A.S. (CZ) | 2018-06-19 | — | — | US | claimed |
| EP-2934592-B1 | C6-C18-ACYLATED DERIVATIVE OF HYALURONIC ACID, METHOD OF PREPARATION THEREOF, NANOMICELLAR COMPOSITION ON ITS BASIS, METHOD OF PREPARATION THEREOF AND METHOD OF PREPARATION STABILIZED NANOMICELLAR COMPOSITION, AND USE THEREOF | CONTIPRO AS (CZ) | 2018-05-16 | — | — | EP | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| EP-2969029-A2 | USE OF COSMETICALLY OR DERMATOLOGICALLY SAFE SUBSTITUTED MICHAEL ACCEPTORS FOR THE PREVENTION, REDUCTION OR PROPHYLAXIS OF THE TYROSINASE ACTIVITY OF THE HUMAN SKIN AND/OR THE LIGHTENING OF THE HUMAN SKIN | Beiersdorf AG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-5843979-A | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-01 | — | — | US | claimed |
| WO-1998032016-A2 | A CYANIDE-FREE LYTIC REAGENT COMPOSITION AND METHOD FOR HEMOGLOBIN AND CELL ANALYSIS | COULTER INTERNATIONAL CORP. (US) | 1998-07-23 | — | — | WO | claimed |
| US-5763280-A | LYSING WITH A SURFACTANT; COMBINING WITH LIGAND TO FORM A STABLE CHROMOGEN WITH HEMOGLOBIN | COULTER INTERNATIONAL CORP. (US) | 1998-06-09 | — | — | US | claimed |
| EP-0802782-A4 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL MYERS SQUIBB CO (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997047355-A1 | REDUCTION OF SKIN SENSITIZATION IN ELECTROTRANSPORT DRUG DELIVERY | ALZA CORPORATION (US) | 1997-12-18 | — | — | WO | claimed |
| US-5686100-A | Prophylactic and therapeutic treatment of skin sensitization and irritation | E.R. SQUIBB & SONS, INC. (US) | 1997-11-11 | — | — | US | claimed |
| EP-0802782-A1 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1996015771-A1 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0612525-A1 | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | HCAR2 4789/4885ABCG2 999/4885SMN1; SMN2 4271/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | HCAR2 4789/4885ABCG2 999/4885SMN1; SMN2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.